# Safety and Efficacy Study of GKL-006RTU in Moderate to Severe Acute Respiratory Distress Syndrome (ARDS)

> **NCT07706855** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Beijing Gene Key Life Technology Co., Ltd** · enrollment: 52 (estimated)

## Conditions studied

- ARDS (Acute Respiratory Distress Syndrome)

## Interventions

- **DRUG:** GKL-006RTU injection
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07706855
- **Lead sponsor:** Beijing Gene Key Life Technology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-11-10
- **Primary completion:** 2028-12-30
- **Final completion:** 2029-05-30
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2026-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07706855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07706855, "Safety and Efficacy Study of GKL-006RTU in Moderate to Severe Acute Respiratory Distress Syndrome (ARDS)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07706855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*